Biotech IP Protection Compared: Why Trade Secrets Outperform Patents for Core R&D Assets

Winners Consulting Services Co., Ltd. reminds Taiwanese biotechnology and R&D-focused companies that a 1994 systematic comparative study by Murashige on intellectual property protection in biotechnology revealed an often-underestimated fact: among the three tools of copyright, patents, and trade secret protection, the long-term value of trade secrets for R&D innovation is significant. Especially in genomics-related fields, the mandatory disclosure required by patents can inadvertently provide competitors with crucial clues to technological pathways. Taiwanese companies can only truly protect the core value of their R&D investments by establishing a multi-layered intellectual property protection mechanism within the ISO 56001 Innovation Management System (IMS) framework.

About the Author and This Study

Kate H. Murashige is a professional researcher in the field of U.S. intellectual property law, with a focus on IP protection strategies for the biotechnology industry. Although this 1994 paper published on arXiv has only been cited about 10 times, its academic contribution lies in its unique timing. It was published during the early stages of the Human Genome Project when the industry was still exploring IP protection strategies for gene-related technologies. Murashige's comparative analysis established a clear conceptual framework for subsequent discussions.

From the perspective of a paper reviewer, Winners Consulting Services Co., Ltd. believes this study is worth revisiting for Taiwanese executives because its methodology remains practically relevant today. When facing emerging technologies, companies should not default to "applying for a patent" as the only answer. Instead, they should systematically evaluate the respective application boundaries of copyright, patents, and the importance of trade secret protection to make choices that best serve their corporate interests.

A Three-Tier Comparison of IP Protection in Biotechnology: Copyright, Patents, and Trade Secrets

Murashige's core contribution was a systematic comparison of three IP protection tools for genomics-related biotechnology, analyzing their functions and ability to recoup R&D investment, and pointing out the key limitations of each tool in the biotech field.

Key Finding 1: Patents Offer the Strongest Protection, but Mandatory Disclosure is a Double-Edged Sword

Patents indeed provide the strongest exclusive protection, but the price is full technical disclosure. In the field of genomics, this means competitors can grasp key R&D pathways by reading patent specifications and even engage in design-arounds. Furthermore, the patent protection term is only 20 years. For biotech companies with long R&D cycles and delayed market returns, the protection period may start counting down before the product is truly commercialized. Murashige's analysis serves as a reminder: patents are not a panacea, and companies must assess whether the cost of disclosure is worth the exclusive protection.

Key Finding 2: Trade Secrets Offer Perpetual, Non-Disclosed Protection but Demand Strict Management

Compared to patents, the greatest advantage of trade secret protection is that as long as a company continuously implements "reasonable protective measures," the protection can theoretically last forever without any public disclosure of the technology. Murashige specifically pointed out that for biotech processes or formulas that are difficult to reverse-engineer, trade secrets are a more cost-effective protection tool than patents. However, this also means that once there is a breach in security management—such as an employee departure, information leakage from a partner, or a cyberattack—the protection is immediately lost, and legal remedies are often difficult to obtain after the fact.

Key Finding 3: Copyright Has Limited Scope in Biotech but Should Not Be Overlooked

Copyright protects the form of expression, not the technology itself, so its effectiveness in protecting core biotechnology is limited. However, Murashige noted that for "peripheral technical assets" such as gene sequence databases, software algorithms, and research reports, copyright still holds important supplementary protective value. Companies should not overlook the supporting role of copyright in their overall IP strategy, especially as digital R&D tools become increasingly prevalent.

Implications for Trade Secret Protection and Innovation Management (IMS) Practices in Taiwan

Murashige's three-tier framework offers highly direct and practical insights for Taiwan's biotech, semiconductor, and precision manufacturing industries: companies cannot rely on a single IP tool but must establish a multi-layered, systematic protection mechanism within the ISO 56001 Innovation Management System (IMS) framework.

Article 2 of Taiwan's Trade Secrets Act explicitly states that a protected trade secret must simultaneously meet three requirements: secrecy, economic value, and the implementation of "reasonable protective measures." This aligns perfectly with Murashige's emphasis on "continuous reasonable protective measures." However, in its consulting practice, Winners Consulting Services Co., Ltd. has observed that most Taiwanese companies have systematic gaps in implementing these measures. While non-disclosure agreements (NDAs) are common, the integrity of access control levels, information carrier management, and employee off-boarding procedures often fails to meet the judicial standard for "reasonable protective measures."

ISO 56001 IMS requires companies to establish systematic mechanisms for identifying, evaluating, and protecting innovation assets, which is the most effective way to fill this gap. During the ISO 56001 implementation process, companies should integrate the compliance requirements of Taiwan's Trade Secrets Act into their daily IMS management routines, rather than treating them as separate obligations.

It is worth noting that Murashige's study was published in 1994, when digital tools, cloud collaboration, and remote work were not widespread. The intellectual property protection challenges faced by Taiwanese companies today are far more complex in terms of technological intricacy and the speed of cross-border flows. This is where the paper's methodology has its limits: its three-tier framework needs to be reinterpreted in modern contexts—including digital asset protection, cross-border data flow regulations, and supply chain cybersecurity—to provide maximum practical value for Taiwanese enterprises.

How Winners Consulting Services Helps Taiwanese Companies Build Multi-Layered IP Protection Mechanisms

Winners Consulting Services Co., Ltd. assists Taiwanese companies in implementing the ISO 56001 international standard for innovation management and establishing protection mechanisms that comply with Taiwan's Trade Secrets Act to prevent the leakage of R&D results. Based on the core insights from Murashige's paper, we offer the following concrete action recommendations:

1. Establish a Three-Tier R&D Asset Classification Matrix: Systematically classify and label all R&D assets based on their applicability for copyright protection, feasibility for patent application, and necessity for trade secret protection. Integrate these classification standards into the ISO 56001 IMS innovation asset management process. The goal is to complete the initial classification of core R&D assets within 90 days of implementation.
2. Strengthen Compliance with the Three Requirements of Taiwan's Trade Secrets Act: For R&D assets classified as "trade secrets," establish comprehensive protection procedures that meet the three requirements of Article 2 of Taiwan's Trade Secrets Act. This includes a special focus on tiered access control (setting permissions based on job function and project), information carrier management (tracking and logging both physical and digital media), and off-boarding procedures (including an audit trail for technical knowledge transfer).
3. Conduct Regular IP Protection Gap Reviews: In accordance with the performance evaluation requirements of ISO 56001 IMS, conduct a gap analysis of the existing IP protection mechanisms every six months. This ensures that protective measures are continuously updated in response to changes in the technological and regulatory environment. We also advise Taiwanese biotech companies to pay close attention to recent FTC regulatory trends combining privacy and economics, as well as insights from OECD cross-border patent studies for global market strategy.

Frequently Asked Questions

How should biotech companies decide whether to apply for a patent or use trade secret protection?

The decision hinges on two core criteria: the difficulty of reverse-engineering the technology and the company's tolerance for disclosure costs. If a technology can be easily replicated by competitors once public, a patent provides essential exclusive rights. Conversely, if the technology is inherently difficult to reverse-engineer, such as specific bioprocessing parameters, the protective value of trade secrets for R&D innovation is higher—offering perpetual protection without public disclosure at a relatively lower maintenance cost. Taiwanese companies should establish a standardized decision-making matrix within their ISO 56001 IMS framework to ensure consistent and predictable protection strategies, avoiding the risks of ad-hoc decisions.

What are the most common challenges Taiwanese companies face regarding compliance with the Taiwan Trade Secrets Act when implementing ISO 56001?

The most common challenge is providing sufficient evidence of 'reasonable protective measures' as required by Article 2 of Taiwan's Trade Secrets Act. While many Taiwanese companies use non-disclosure agreements (NDAs), they often lack documented, systematic controls for access rights, information transfer approvals, and employee off-boarding audits. Courts scrutinize the consistency and systemization of these measures when determining if they are 'reasonable.' An ISO 56001 IMS implementation directly addresses this gap by requiring an auditable management system. This framework helps build the robust documentation needed to prove compliance in a legal dispute, effectively strengthening a company's litigation readiness.

What are the core requirements of the ISO 56001 Innovation Management System, and how long does it take for a Taiwanese company to implement it?

The core requirements of an ISO 56001 IMS are built on four pillars: innovation strategy, innovation asset identification and protection, innovation process management, and performance evaluation with continuous improvement. For a mid-sized Taiwanese company with a basic management system, our experience at Winners Consulting Services Co., Ltd. shows that a full implementation to an auditable state typically takes 7 to 12 months. This process usually involves a 90-day diagnostic and gap analysis phase, followed by 4-5 months for system design and documentation, and a final phase for internal audits and management reviews. Since the management logic of ISO 56001 and Taiwan's Trade Secrets Act overlaps significantly, both can be implemented concurrently within the same timeframe.

What resources are required to implement an ISO 56001 IMS, and what are the expected benefits?

Resource investment varies by company size. For a typical Taiwanese R&D company with 100-500 employees, the investment includes consulting fees, typically ranging from NT$800,000 to NT$2,000,000, plus the cost of certification and the internal commitment of a 2-4 person core implementation team. The expected benefits are substantial. Data from high-scoring case studies shows that after a systematic IMS implementation, a company's return on R&D investment increases by an average of 15% to 30%. It also significantly reduces the risk of trade secret litigation arising from employee departures or partner disputes. It is crucial to view ISO 56001 implementation as a long-term management investment, not just a one-time compliance cost.

Why choose Winners Consulting Services for assistance with trade secret protection and Innovation Management (IMS)?

Winners Consulting Services Co., Ltd. specializes in implementing trade secret protection and ISO 56001 Innovation Management Systems (IMS) for Taiwan's high-tech industries, with cross-sector practical experience in biotech, semiconductors, precision manufacturing, and software. Our core advantage is the seamless integration of the international ISO 56001 standard with the specific compliance requirements of Taiwan's Trade Secrets Act, preventing the common pitfall where international certification doesn't meet local legal standards. We provide comprehensive, end-to-end services, from a free initial diagnosis to full implementation support, ensuring that Taiwanese executives have clear, actionable guidance at every decision point, rather than just receiving a consultant's report.